(Health Korea News / Soon-ho Lee) An increasing number of pharmaceutical companies are appointing outsiders to key positions in the company. In particular, well-known figures in the industry have recently become free agents, and fast-moving pharmaceutical companies have recruited them to play key roles. As many of them come from large domestic pharmaceutical companies and multinational companies, it is expected that their experience and know-how will create synergy with the company.
#huonsrecently appointed Park Kyung-mi, former vice president of Genome & Company, as vice president of new growth R&D.
Vice President Park graduated from Seoul National University’s Department of Pharmaceutical Sciences and earned master’s and doctoral degrees from the same graduate school’s Department of Pharmacy (majoring in physical pharmacy). He served as clinical manager of the development team at CJ Pharmaceutical Business Division, director in charge of the clinical team at Hanmi Pharmaceutical, executive director of CHA Biotech’s development division, managing director in charge of product development at Chong Kun Dang’s development division, and vice president of Genome & Company.
He has served as a member of the clinical development committee of the Korea Pharmaceutical Association and a member of the project evaluation/investment review committee of the pan-governmental New Drug Development Project Group, as well as an investment review committee member of the National New Drug Development Project Group and the chairman of the Research and Development Committee of the Korea Industrial Pharmaceutical Association. We have extensive experience throughout the entire process, from establishing clinical development plans to approval and sales.
Huons expects that the role of new Vice President Park Kyung-mi will strengthen communication between research organizations and further increase R&D synergy.
#Dong-A STrecently recruited Choi Hyeong-seok, former Head of Antibody Technology Lab at Samsung BioLogics, as an executive-level researcher.
Research Fellow Choi graduated from the Department of Genetic Engineering at Sungkyunkwan University, received a master’s degree in life sciences and immunology from Pohang University of Science and Technology (POSTECH), and a doctorate in systems biotechnology and metabolic engineering from the Korea Advanced Institute of Science and Technology (KAIST).
Afterwards, he led the development of antibody platforms through Hanwha Chemical, GC Green Cross, and Samsung BioLogics. Dong-A ST is expected to participate in biosimilar research, which Dong-A ST is working on, including antibody drug conjugate (ADC) research with Aptis.
#chong kundangrecruited Jeon Seung-ho, former CEO of Daewoong Pharmaceutical, as an advisor last September. It is known that the former advisor served as a management advisor at Chong Kun Dang.
The former advisor served in key positions at Daewoong Pharmaceutical from 2003 to 2023. After serving as head of the global strategy team and head of the global business division, he served as CEO of Daewoong Pharmaceutical for six years starting in 2018. During the period he served as CEO, he not only achieved business results such as producing ‘Pexuclu’, a new drug for gastroesophageal reflux disease, and ‘Enblo’, a new drug for diabetes, but also significantly improved performance, proving his management capabilities.
Chong Kun Dang not only signed a technology export contract worth $1.305 billion (approximately KRW 1.73 trillion) with multinational pharmaceutical company Novartis, but also conducted research and development (R&D) in various fields such as cell and gene therapy (CGT) and antibody-drug conjugate (ADC). We are focusing on R&D.
The recruitment of advisor Jeon Seung-ho is interpreted as Chong Kun Dang’s move to expand its global business capabilities.
#Samil PharmaceuticalLast September, Shin Yu-seok, former head of Dong-A ST’s overseas business division, was hired as general president of the sales and marketing division.
The new president, Yoo-seok Shin, graduated from Seoul College of Pharmacy and earned a master’s degree from Seoul National University’s Graduate School of Pharmacy. He started out as an employee at Pfizer Pharmaceuticals in Korea in 1999, then worked as a CNS marketing team leader at GSK Korea and a marketing executive at GSK Taiwan, providing theory and practice across the entire pharmaceutical industry. He is known as the industry’s best expert who is well versed in
After moving to Dong-A ST in 2010, he held various major positions including head of marketing, head of medical business division, and head of overseas business, leading the company’s growth in various fields, including academics, sales, marketing, new businesses, and global businesses.
#GenuoneScienceappointed former Hugel CEO Son Ji-hoon as its new CEO last September. The recruitment of new CEO Son is aimed at solidifying the company’s domestic position based on its production capabilities and strengthening its overseas competitiveness by securing new growth engines.
New CEO Ji-hoon Son graduated from Korea University’s Department of Economics and earned an MBA from Boston University Graduate School of Business. Afterwards, he started his career at BMS headquarters and worked for over 35 years in domestic and foreign pharmaceutical companies, including as Executive Director of Dong-A Pharmaceutical’s Global Business Department, CEO of Baxter Korea, CEO of Dongwha Pharmaceutical, and CEO of Hugel.
While serving as CEO of Hugel, he was recognized for his management skills by not only obtaining approval for his representative products in the U.S., Europe, and China, but also recording record-high sales every year.
An industry official said, “Recent hiring of executive-level personnel by pharmaceutical companies is focused on R&D and global business,” adding, “This means that the pharmaceutical industry is focusing on new drug development and export rather than generic business in the domestic market.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
